1/4/24 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient January 4, 2024j3ff1 Read More
12/11/23 – RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development December 11, 2023j3ff1 Read More
10/12/23 – RespireRx Pharmaceutical Inc’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services October 12, 2023j3ff1 Read More
8/9/23 – RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company August 9, 2023j3ff1 Read More
5/24/23 – ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs May 24, 2023j3ff1 Read More
4/5/23 – RespireRx Pharmaceuticals Inc. Establishes Research Collaboration with University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders April 5, 2023j3ff1 Read More
4/3/23 – RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation April 3, 2023j3ff1 Read More
3/28/23 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Joseph Siegelbaum as an Independent Member of the Board of Directors March 28, 2023j3ff1 Read More
3/1/23 – ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd March 1, 2023j3ff1 Read More
2/1/23 – ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits February 1, 2023j3ff1 Read More
